Geographic Area – Page 4

Novo Nordisk’s Pipeline Cull Prompts Hopes of Strategic Shift

1 month ago talkbio0Tagged competition, GLP-1/GIP co-agonist, Leadership Change, Market, Nordisk, Obesity, pipeline cull, R&D pipeline, semaglutide, strategic shift, Wegovy

Novo Nordisk; pipeline cull; GLP-1/GIP co-agonist; obesity drugs; leadership change; strategic shift; semaglutide; Wegovy; R&D pipeline; market competition

Trump Announces Massive Pharma Tariffs Up to 250%, Signals Enforcement Within Days

1 month ago talkbio0Tagged Biopharma, Canada, fentanyl crisis, international trade, Pharma Tariffs, Sectioning technique, tariff increase, Transplant Registry Unified Management Program

Trump; pharma tariffs; tariff increase; biopharma; Canada; Section 301; international trade; fentanyl crisis

Praxis touts ‘best-in-disease’ epilepsy data, but shares dip

1 month ago talkbio0Tagged anti-seizure medication, Clinical Research, Clinical Trials, Epilepsy, focal onset seizures, Market, Praxis Precision Medicines, Radiant heater, Seizures, vormatrigine

Praxis Precision Medicines; epilepsy; vormatrigine; RADIANT study; focal onset seizures; Phase 2 trial; seizure reduction; clinical trial; anti-seizure medication; stock market

Sanofi Acquires China Rights to Arrowhead’s Plozasiran for $395 Million

1 month ago talkbio0Tagged Arrowhead, China, Familial chylomicronemia syndrome, Hypertriglyceridemia, milestone payments, Partnership, Plozasiran, RNA Interference, sanofi, Severe (severity modifier)

Sanofi; Arrowhead Pharmaceuticals; Visirna Therapeutics; Plozasiran; China rights; RNA interference; Familial chylomicronemia syndrome; Severe hypertriglyceridemia; biotech partnership; milestone payments

Alnylam Surpasses $50B Market Cap as Amvuttra Heart Disease Launch Impresses Wall Street

2 months ago talkbio0Tagged Alnylam, Amvuttra, ATTR-CM, Caps, earnings, Heart Diseases, Market, revenue growth, Stock Surge

Alnylam Pharmaceuticals; market cap; Amvuttra; heart disease; ATTR-CM; stock surge; Q2 2025 earnings; revenue growth

Ignoring China’s Biotech Industry Is No Longer an Option: Recent Developments and Implications

2 months ago talkbio0Tagged China, Clinical Trials, Dosage Forms, Ecosystem, global drug development, Industry, innovation, Legal patent, US-China competition

China biotech industry; global drug development; clinical trials; innovation ecosystem; pharmaceutical R&D; biotech patents; US-China competition

Viridian Licenses Promising Eye Disease Candidates to Kissei for Japanese Market

2 months ago talkbio0Tagged Antibodies, Biopharma, Clinical Trials, Dosage Forms, Japan, Kissei, Partnership, Thyroid associated opthalmopathies, Veligrotug, Viridian, VRDN-003

Viridian Therapeutics; Kissei Pharmaceutical; veligrotug; VRDN-003; thyroid eye disease; Japan partnership; anti-IGF-1R antibodies; clinical trials; biopharma deal

FDA Investigates Elevidys Death; Sarepta and Roche Deny Link to Gene Therapy

2 months ago talkbio0Tagged Brazil, ELEVIDYS, gene therapy, Market, Muscular Dystrophy, Duchenne, Patient Death, Roche (company), Safety, Suspensions, United States Food and Drug Administration

FDA; Elevidys; Sarepta Therapeutics; Roche; gene therapy; Duchenne muscular dystrophy; patient death; Brazil; market suspension; safety concerns

CHMP Recommends Against Approval of Elevidys Gene Therapy in Europe, Dealing Blow to Sarepta and Roche

2 months ago talkbio0Tagged CHMP, ELEVIDYS, EMBARK trial, Europe, gene therapy, Multiple Acyl Coenzyme A Dehydrogenase Deficiency, Muscular Dystrophy, Duchenne, negative opinion, Roche (company)

CHMP; Elevidys; Sarepta; Roche; gene therapy; Duchenne muscular dystrophy; EMA; negative opinion; Europe; EMBARK trial

Lack of Transparency Tarnishes Sarepta’s Sheen as Patient Deaths Trigger FDA Battle

2 months ago talkbio0Tagged ELEVIDYS, gene therapy, lack of transparency, Market, Muscular Dystrophies, Limb-Girdle, Muscular Dystrophy, Duchenne, patient deaths, Regulatory Action, United States Food and Drug Administration, Withdraw (activity)

Sarepta Therapeutics; Elevidys; patient deaths; FDA; lack of transparency; gene therapy; market withdrawal; regulatory action; limb-girdle muscular dystrophy (LGMD); Duchenne muscular dystrophy